1Mc Meekin DS, Gordon A, Fowler J et al. A phase Ⅱ trial of arzole, a selective estrogen response modulator in patients with recurrent or advanced endometrial cancer. Gynecol Oncol, 2003, 90:64
2Quinn MA. Hormonal treatment of endometrial cancer. Hematol Oncol Clin North Am, 1999, 13:163
3Blok LJ, De Rulter PE, Ku EC et al. Progestagenic effects of tibolone on human endometrial cancer cells. J Clin Endocrinol Metab, 2003, 88 (5) : 2327
4Emons G, Heyl W. Hormonal treatment of endometial cancer. J Cancer Res Clin Oncol, 2000, 126:619
5Niva K, Tagami K, Lian Z et aL Outcome of fertility - preserving treatment in young women with endometrial carcinoma. BJOG, 2005, 112 : 317
6Chyong - Huey L, Huei - Jean H. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Current Opinion in Obstetrics and Gynecology, 2006, 18 : 29
7Huang SY, Lai CH, Jung SM et al. Ovarian metastasis in a nulliparous woman with endometrial adenocareinoma failing conservative treatment: case report. Gynecol Oncol, 2005, 97:652
8Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility - preserving treatment. Eur J Obstet Gynecol Reprod Biol, 2004, 117:132
9GofliebWH, Beiner ME, Shalmon Bet al. Outcome of fertilitity - sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol, 2003, 102 (4) : 718
10Dai D, Albitar L, Nguyen T et al. A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral -mediated progesterone receptor expression. Mol Cancer Ther, 2005, 4 (1): 169
2[1]Sitteeri PK. Review of studies on estrogen biosynthesis in the human.Cancer Res, 1982, 42:3269-3276
3[2]BulunSE, Mahendroo MS, Simpson ER.Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J Clin Endocrinol Metab, 1993, 76:1458- 1463
4[3]YamaguchiF, SayaH, Bruner JM, etal. Differential expression of two fibroblast growth factor- receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA, 1994, 91:484 - 488
5[4]KagaK, SasanoH, HaradeN, etal. Aromatase in human common epithelial ovarian neoplasms.Am J Pathol, 1996, 149:45-51
6[5]Corbin CJ, Graham- Lorence S, McPhaul M, et al. Isolation of a full - length cDNA insert encoding human aromatase system cytochrome p450 and its expression in nonstroidogenic cells. Proc Natl Acad Sci USA,1988, 85: 8948- 8953
7[7]Brodie AMH, Schwarzel WC, Shaikh AA, et al. The effect of an aromatase inhibitor, 4- h ydroxy- 4- androstene- 3, 17- dione on estrogen- dependent process in reproduction and breast cancer, Endocrinol,1977, 100: 1684-1695
8[8]Miller WR, Anderson TJ, Tack WLJ. Relationship between tumor aromatase activity, tumor characteristics and response to therapy. J Steroid Biochem Mol Biol, 1990, 37:1055 - 1059
9[9]Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization , regulation , and functional correlations. J Clin Endocrinol Metab, 1998, 83: 2479- 2485
10Shimizu M,Saitch Y,Itoh H.Immunohistochemical staining of H-ras oncogenic product in normal,benign and malignant human pancreatic tissues[J].Hum Pathol,1990,21(3):607.
